ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018
(firmenpresse) - Leiden, The Netherlands, November 13, 2018
Prof. Melief will be the second recipient of the ESMO Immuno-Oncology Award, which was created in 2017 in commemoration of European cancer research and treatment pioneer Prof. Georges Math
In addition to his role at ISA Pharmaceuticals, Prof. Melief is Professor Emeritus in tumor immunology at the Leiden University Medical Center in the Netherlands. He focuses on the development of effective immunotherapies for virus-induced tumors and has created the concept of synthetic long peptide (SLP) vaccines for the treatment of cancer patients. Prof. Melief and his team were able to show the clinical effectiveness of these therapeutic vaccines in patients with pre-malignant lesions caused by Human Papilloma Virus type 16 (HPV-16).
Among the most promising results obtained to date, Melief and his team found that a combination of SLP vaccination and standard chemotherapy strengthened cervical cancer patients
Prof. George Coukos and John Haanen, Scientific Co-Chairs of the upcoming congress, outlined the reasons for nominating Cornelis Melief:
###
Contact & Media Inquiries:
akampion
Dr. Ludger WessInes-Regina Buth
Managing PartnerManaging Partner
Tel. +49 40 88 16 59 64Tel. +49 30 23 63 27 68
info(at)akampion.com
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic immunotherapeutics against cancer and persistent viral infections. The company has built a proprietary immunotherapy platform based on the Synthetic Long Peptide (SLP®) concept and AMPLIVANT® technology. SLP® immunotherapies are designed to fully harness and direct the body’s own defenses towards fighting the disease. In December 2017, ISA Pharmaceuticals closed a clinical immuno-oncology collaboration with Regeneron to advance its SLP® lead compound ISA101, an immunotherapy targeting human papillomavirus type 16 (HPV16)-induced cancer, in combination with Cemiplimab (REGN2810), a PD-1 (programmed cell death protein 1) antibody. In addition, ISA develops SLP® immunotherapies to advance novel treatment options for orphan indications.
For more information, please visit www.isa-pharma.com.
SLP® and AMPLIVANT® are registered trademarks in Europe.
Datum: 13.11.2018 - 04:04 Uhr
Sprache: Deutsch
News-ID 1543921
Anzahl Zeichen: 3440
contact information:
Contact person: Ines-Regina Buth
Town:
Berlin
Phone: +493023632768
Kategorie:
Healthcare & Medical
Typ of Press Release: Personalie
type of sending: Veröffentlichung
Date of sending: 13.11.2018
Anmerkungen:
Diese Pressemitteilung wurde bisher 315 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ISA Pharmaceuticals´ Chief Scientific Officer Prof. Cornelis Melief Receives ESMO Immuno-Oncology Award 2018
"
steht unter der journalistisch-redaktionellen Verantwortung von
akampion (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
